Tenet Healthcare (NYSE:THC) Stock Price
Tenet Healthcare (NYSE:THC) is currently trading at US$268.52, with a fair value estimate of US$250, indicating it is overvalued by 7.4%. Analyst narratives provide varying perspectives, with some highlighting growth drivers like behavioral care and outpatient trends, while others caution about M&A risks and Medicaid reliance. Recent insider transactions show net selling activity.
Tenet Healthcare stock hits all-time high at 270.79 USD By Investing.com
Tenet Healthcare's stock reached an all-time high of $270.79 USD, reflecting a 54.4% increase over the past year and strong investor confidence. The company's P/E ratio of 10.46 and PEG ratio of 0.15 suggest an attractive valuation. Recent strong Q2 2026 results and raised full-year outlook have led several analysts to increase their price targets, indicating a positive outlook for the company's financial trajectory.
Can Tenet Healthcare's Hospital Growth Keep Earnings Momentum Going?
Tenet Healthcare's (THC) Hospital Operations segment continues to drive strong earnings, with adjusted admissions increasing 2.6% year over year and revenue per adjusted admission rising 3.3% in Q2 2026. This growth is attributed to healthy patient demand, a better mix of services, and a focus on higher-acuity care, leading to a significant 22.3% jump in hospital adjusted EBITDA. Despite some pressure from weaker exchange enrollment, the company's cost-management efforts and a positive outlook for continued improvement position the segment as a strong tailwind for THC's earnings.
Can Tenet Healthcare's Hospital Growth Keep Earnings Momentum Going?
Tenet Healthcare Corporation's Hospital Operations segment showed strong earnings growth in Q2 2026, with increased adjusted admissions and revenue per patient, leading to significant margin improvement. Despite some pressure from weaker exchange enrollment, the company's focus on high-acuity care, cost management, and strong commercial revenues are driving profitability. Peers like Universal Health Services and HCA Healthcare also reported solid hospital growth, indicating a healthy demand for hospital care.
Tenet Healthcare director Roy Blunt sells $157,608 in company stock
Tenet Healthcare director Roy Blunt sold 600 shares of company stock for $157,608 on August 5, 2026, at an average price of $262.68 per share. This transaction occurred while the stock was trading near its 52-week high, despite analysis suggesting it remains undervalued. The sale follows Tenet Healthcare's strong second-quarter 2026 results and raised full-year outlook, which led to multiple analyst price target increases.
Tenet Healthcare director Roy Blunt sells $157,608 in company stock
Tenet Healthcare director Roy Blunt sold 600 shares of company stock worth $157,608 on August 5, 2026, with the stock trading near its 52-week high. This sale follows Tenet Healthcare's strong second-quarter 2026 results, which surpassed Wall Street expectations and led to raised full-year outlooks and increased price targets from several analyst firms.
Tenet Healthcare (NYSE:THC) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen downgraded Tenet Healthcare (NYSE:THC) from a "strong-buy" to a "buy" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $273. The company recently reported strong quarterly earnings of $6.12 per share, exceeding estimates, with revenue increasing 6.8% year over year to $6.04 billion. Insiders have sold nearly $9.8 million in stock in the past 90 days, while institutional investors hold 95.44% of the shares.
Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
Tenet Healthcare (THC) is currently considered a strong value stock, boasting a Zacks Rank #1 (Strong Buy) and an "A" grade for Value. Key metrics like a PEG ratio of 0.81 (compared to an industry average of 1.56), a P/B ratio of 3.07 (vs. industry 3.67), and a P/CF ratio of 7.51 (vs. industry 8.96) suggest that the stock may be undervalued. These indicators, combined with a strong earnings outlook, position THC as an attractive investment for value-oriented investors.
Is Tenet Healthcare (THC) Overvalued Following Higher 2026 Adjusted EPS Guidance?
Tenet Healthcare (THC) has seen a significant surge in its share price and an increase in its 2026 adjusted EPS guidance, leading to questions about its valuation. While some analysts deem it overvalued at $250 compared to its last close of $267.05, others note its P/E ratio is lower than the industry average, suggesting potential mispricing or reflecting its high debt. The stock presents a mixed sentiment with strong momentum balanced against identified risks and rewards.
Tenet Healthcare (THC) Could Be 7% Above Fair Value As Golden Cross Draws Focus
Tenet Healthcare (THC) recently experienced a "golden cross," with its 50-day moving average surpassing its 200-day average, signaling positive momentum. Despite a significant stock price increase, analysts project the company to be 6.7% overvalued, with a fair value of $250 against its current trading price of $266.79. However, the article notes that THC's P/E ratio is considerably lower than its peers, suggesting potential for either risk or opportunity.
Tenet Healthcare (NYSE:THC) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Tenet Healthcare (NYSE:THC) from a "hold" to a "strong-buy" rating. This upgrade comes after Tenet reported strong quarterly earnings, beating analyst estimates with $6.12 earnings per share and revenue of $6.04 billion. Despite recent insider stock sales totaling $9.8 million, institutional investors hold a significant 95.44% stake in the company.
Assenagon Asset Management S.A. Lowers Stock Position in Tenet Healthcare Corporation $THC
Assenagon Asset Management S.A. significantly reduced its stake in Tenet Healthcare Corporation ($THC) by 60.7% in the second quarter, selling 74,968 shares but still retaining 48,533 shares valued at approximately $9.08 million. Despite this, institutional investors collectively own 95.44% of THC, and Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $272.25. The company recently reported strong quarterly earnings, beating analyst estimates, although insiders have sold a substantial amount of shares.
Here's How Much You'd Have If You Invested $1000 in Tenet Healthcare a Decade Ago
An investment of $1000 in Tenet Healthcare (THC) ten years ago would now be worth $10,130.81, representing a 913.08% gain, outperforming the S&P 500 and gold. The company benefits from higher-acuity services, strong commercial revenues, and the expansion of its ambulatory care platform, USPI. Despite concerns about labor costs and valuation, analysts forecast further upside for THC.
Tenet Healthcare (THC) Director Tammy Romo Sells 7,422 Shares
Tenet Healthcare (THC) Director Tammy Romo sold 7,422 shares on August 7, 2026, for approximately $1.95 million, reducing her total holdings to 28,284 shares. This transaction is part of a trend of 21 insider sells and zero buys over the past year, suggesting a bearish insider sentiment. The stock is currently trading at $263.03, significantly above its estimated intrinsic value of $186.10, making it "Significantly Overvalued" according to GuruFocus.
Tenet Healthcare (NYSE:THC) Director Tammy Romo Sells 4,922 Shares of Stock
Tenet Healthcare Director Tammy Romo sold 4,922 shares of THC stock for over $1.3 million on August 6th, and an additional 2,500 shares on August 7th, reducing her direct stake by 13.78%. The company recently reported strong quarterly earnings of $6.12 per share, exceeding estimates, with revenue increasing by 6.8% year-over-year. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $272.25.
Tenet Healthcare director Tammy Romo sells $1.95m stock By Investing.com
Tammy Romo, a director at Tenet Healthcare Corp. (NASDAQ:THC), sold approximately $1.95 million worth of common stock in two transactions earlier this month, involving 7,422 shares at prices between $260.83 and $264.15. These sales occurred as Tenet shares approached their 52-week high, following a 56% gain over the past year. Despite the sales, Romo still directly holds 28,284 shares, and the company recently reported strong Q2 2026 results, leading to increased price targets from several analysts.
Tenet Healthcare (NYSE:THC) Director Sells 2,500 Shares of Stock
Tenet Healthcare Director Tammy Romo sold 2,500 shares of company stock for over $652,000, reducing her position by 8.12%. This follows a previous sale of 4,922 shares. The stock price closed at $260.33, near its 52-week high, after the company reported strong quarterly earnings and received a "Moderate Buy" consensus rating from analysts.
Tenet Healthcare’s (THC) Turnaround Is Working, but Can Its Growth Last?
Tenet Healthcare (THC) has seen a significant turnaround, with its stock surging over 270% in five years due to an expanded ambulatory surgery platform, focus on higher-acuity care, and improved cash generation. The company recently reported strong Q2 2026 results, exceeding Wall Street estimates and raising its full-year outlook, driven by hospital profitability and outpatient surgery growth. However, concerns remain about the sustainability of its growth if surgical volumes soften and payer-mix pressures increase, especially as its surgery business sees fewer procedures despite higher revenue per case.
TENET HEALTHCARE CORP : MIZUHO RAISES TARGET PRICE TO $290 FROM $250
Mizuho has increased its target price for Tenet Healthcare Corp (THC.N) to $290, up from the previous $250. This adjustment reflects an updated outlook from the analyst firm regarding the healthcare company's valuation. The news was reported by Reuters.
TENET HEALTHCARE CORP : MIZUHO RAISES TARGET PRICE TO $290 FROM $250
Mizuho has increased its target price for Tenet Healthcare Corp (THC.N) from $250 to $290. This adjustment reflects Mizuho's updated outlook on the company's financial prospects. The information was reported by Reuters.
Tenet Healthcare Corporation (THC) Stock Analysis: A Promising 7.49% Upside Potential for Investors
Tenet Healthcare Corporation (THC) shows a promising 7.49% upside potential, with its stock currently trading at $262.13. The company, a diversified healthcare services provider with a market capitalization of $21.11 billion, exhibits strong operational metrics including 6.80% revenue growth and a 37.34% return on equity. Analyst sentiment is highly positive, with an average target price of $281.76, supported by bullish technical indicators, though the Relative Strength Index suggests the stock is currently overbought.
Polianta Ltd Acquires New Shares in Tenet Healthcare Corporation $THC
Polianta Ltd recently acquired 10,700 shares of Tenet Healthcare Corporation (NYSE:THC) during the second quarter, valued at approximately $2.0 million, making it their 27th largest holding. Tenet Healthcare reported strong quarterly earnings, surpassing analyst estimates, and raised its fiscal 2026 EPS guidance. While institutional ownership is high and analysts generally maintain a "Moderate Buy" rating with an average price target of $271.00, recent insider activity has shown significant selling of shares.
Tenet Healthcare Corporation (THC) Stock Forecasts
Argus has increased its rating for Tenet Healthcare Corporation (THC) to a BUY as of July 29, 2026. Tenet Healthcare, a Dallas-based healthcare services organization, operates acute and specialty hospitals and numerous ambulatory surgery centers across the US. The current price for THC is $262.13, but a specific price target is not provided in this summary.
Director Roy Blunt Sells 600 Shares of Tenet Healthcare Corp (THC)
Director Roy Blunt sold 600 shares of Tenet Healthcare Corp (THC) for approximately $157,608 on August 5, 2026. This sale contributes to a trend of 20 insider sells and zero buys at the company over the past year. Despite attractive operational metrics, GuruFocus's GF Value assesses THC as significantly overvalued by 42%, trading at $262.68 against an intrinsic value of $184.42, suggesting caution for investors.
Tenet Healthcare director Roy Blunt sells $157,608 in shares By Investing.com
Tenet Healthcare director Roy Blunt sold 600 shares of the company's common stock for $157,608 on August 5, 2026. This transaction occurred as the stock trades near its 52-week high, following strong Q2 2026 results that surpassed analyst expectations and led to raised full-year outlooks and increased price targets from several firms. Despite the sale, InvestingPro analysis indicates the stock is undervalued with a "GREAT" financial health score.
Here’s How Much You Would Have Made Owning Tenet Healthcare Stock In The Last 15 Years
Tenet Healthcare (NYSE: THC) has outperformed the market over the past 15 years with an average annual return of 18.6%. An initial investment of $100 in THC stock 15 years ago would now be worth $1,323.89, demonstrating the power of compounded returns. The company currently has a market capitalization of $21.11 billion.
Karmanos Cancer Hospital sues Detroit Medical Center over threats to patient care services
Karmanos Cancer Hospital is suing Detroit Medical Center (DMC) and its parent company Tenet, alleging threats to terminate or reduce essential patient care services. Karmanos claims DMC has restricted its expansion efforts and implemented unjustified cost increases for support services, transforming a business disagreement into a patient care issue. The lawsuit is a preemptive measure to ensure continued high-quality cancer care for patients, although Karmanos states patient care will not be disrupted despite the ongoing dispute.
FMR LLC (THC) reports 3.99M-share, 4.6% Tenet Healthcare stake in 13G/A
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, reporting a beneficial ownership stake of 3,994,545.39 shares in Tenet Healthcare Corp (THC), which represents 4.6% of the common stock outstanding. FMR LLC holds sole dispositive power over all these shares and sole voting power over 3,985,108.16 shares. This filing indicates a passive investment, as the ownership percentage is below 5%, and no single other person holds more than five percent of Tenet Healthcare's outstanding common stock through FMR's managed accounts.
McLaren sues DMC over Karmanos contract dispute
McLaren Health Care has filed a lawsuit against Detroit Medical Center (DMC) and Tenet Healthcare over a contract dispute concerning the Karmanos Cancer Institute. The lawsuit was filed on August 6, 2026, and seeks to resolve issues related to their agreement. Karmanos Cancer Institute is highlighted as one of the 40 National Cancer Institute-designated centers in the U.S.
Tenet Healthcare's (NYSE:THC) Earnings Are Of Questionable Quality
Tenet Healthcare reported robust earnings, but an analysis suggests the quality is questionable due to a significant contribution from "unusual items." These one-off gains boosted statutory profit by US$313m, implying that future profitability might be lower if these items don't repeat. Despite this, the company has shown impressive EPS growth over the last three years.
Tenet Healthcare's (NYSE:THC) Earnings Are Of Questionable Quality
Tenet Healthcare recently reported strong earnings, but an analysis suggests that investors might be overlooking details beneath the profit numbers. The company's statutory profit was significantly boosted by US$313 million in unusual items, which are typically one-off occurrences. This raises concerns about the sustainability of Tenet Healthcare's reported profitability, implying that its true underlying earnings power may be less than what the statutory figures suggest if these unusual items do not repeat.
Tenet Healthcare Corporation (THC) Stock Forecasts
The article "Tenet Healthcare Corporation (THC) Stock Forecasts" was published on Yahoo Finance but currently displays an error preventing content retrieval. The page structure indicates it should contain research reports and trade ideas related to THC. No specific forecast information is available due to the error.
TENET HEALTHCARE CORP SEC Filing (Aug 5, 2026)
This article reports on a TENET HEALTHCARE CORP (THC) SEC Form 144 filing from August 5, 2026. The filing indicates a proposed sale of 600 shares of common stock with an aggregate market value of $157,606.35, acquired through restricted stock vesting on May 23, 2025. The transaction is set to occur on August 5, 2026, via Fidelity Brokerage Services LLC on the NYSE.
Tenet Healthcare Corporation (THC) Stock Analysis: Evaluating a Strong 8.91% Potential Upside
Tenet Healthcare Corporation (THC) shows a strong potential upside of 8.91%, with a current market capitalization of $20.51 billion. The company exhibits robust financial performance, including a 6.80% revenue growth, a 37.34% return on equity, and over $2.24 billion in free cash flow. Analyst ratings are largely positive, with a consensus target price suggesting significant growth from its current stock price.
Tenet Healthcare (THC) Stock Still Looks Cheap On Earnings
Tenet Healthcare (THC) has delivered strong returns over the past five years, but the market still undervalues it based on its P/E ratio, which is significantly lower than the healthcare industry average. The article discusses why the stock appears cheap on earnings and presents both bull and bear cases for its future performance, focusing on outpatient growth versus execution and reimbursement risks.
Tenet Healthcare COO Lisa Foo sells $2.58m in stock
Lisa Y. Foo, COO of Tenet Healthcare Corp. (NASDAQ:THC), sold 10,000 shares of company stock for a total of $2.58 million on July 29, 2026. This transaction occurred as the stock trades near its 52-week high after a significant gain, and follows strong Q2 2026 results that surpassed analyst expectations, leading to raised price targets from several firms.
Free cash flow per share of Tenet Healthcare Corporation – HAM:THC1
This article provides financial information for Tenet Healthcare Corporation (HAM:THC1), specifically focusing on its free cash flow per share. It appears to be a stub or a section of a larger financial data page on TradingView, indicating where this specific financial metric can be found. The content is part of a financial data service provided by TradingView, detailing various market and reference data providers.
Tenet Healthcare (THC) EVP and COO Lisa Foo Sells 10,000 Shares
Tenet Healthcare's EVP and COO Lisa Foo sold 10,000 shares of THC on July 29, 2026, for approximately $2.58 million, continuing a pattern of insider selling with no insider purchases over the past year. While the stock's P/E ratio is lower than the industry median, GuruFocus's GF Value suggests the stock is "Significantly Overvalued," trading at 1.41 times its intrinsic value of $183.33. This insider selling, coupled with the overvaluation, suggests caution for investors despite some mixed guru ownership.
Form 4 Tenet Healthcare Corporation For: 31 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Tenet Healthcare Corporation for the period ending July 31. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, and beneficial owners of more than 10% of a class of the company's equity securities, to report changes in their ownership of the company's stock. The article itself is very brief, mainly serving as a headline for this financial disclosure.
Tenet Healthcare COO Lisa Foo sells $2.58m in stock
Tenet Healthcare COO Lisa Foo sold 10,000 shares of company stock worth $2.58 million on July 29, 2026, with the shares trading near their 52-week high after a 61% gain. The sale follows strong second-quarter 2026 results where Tenet Healthcare exceeded analyst expectations and raised its full-year outlook, leading to increased price targets from several analyst firms.
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
Tenet Healthcare (THC) is gaining investor attention due to strong recent stock performance, outperforming both the S&P 500 and its industry. The company has a Zacks Rank #2 (Buy), driven by positive earnings estimate revisions and consistent outperformance of revenue and EPS expectations. Its valuation also appears favorable, graded 'A' on the Zacks Value Style Score.
Executive VP & Chief Information Officer Paola Arbour Sold A Bunch Of Shares In Tenet Healthcare
Paola Arbour, the Executive VP & Chief Information Officer at Tenet Healthcare, recently sold US$2.7m worth of shares, decreasing her holding by 37%. This follows a larger sale by Chairman & CEO Saumya Sutaria in the last year, who sold US$15m worth of shares. While insider selling might seem negative, the company still maintains high insider ownership and growing profits, though there are some warning signs noted in their investment analysis.
Tenet Healthcare Corp (THC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Tenet Healthcare Corp (THC), outlining its current price momentum, support and resistance levels, and signals from various technical indicators. It notes a current price momentum score of 5.75, placing it within the Healthcare Providers & Services industry, and suggests suitability for range-bound swing trading. The analysis also details buy/sell signals from indicators like MACD, RSI, and different moving averages, while emphasizing that technical analysis is for reference only.
THC|Tenet Healthcare Corp|Price:257.660|Chg%:-4.970
TradingKey provides a comprehensive stock analysis for Tenet Healthcare Corp (THC), indicating that its fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Healthcare Providers & Services industry. The report highlights high institutional ownership and analysts' "Buy" ratings with a target price of $271.78, suggesting an upward trend in the medium term. However, despite strong market performance, technical indicators do not fully support the current trend, positioning the stock for range-bound swing trading between support and resistance levels.
TENET HEALTHCARE CORP 2026: Revenue $5.63B, EPS $9.84— 10-Q Summary
TENET HEALTHCARE CORP (THC) reported strong financial results for the quarter ended 2026, with revenue reaching $5.63 billion and diluted EPS at $9.84. This performance was attributed to increased hospital and ambulatory volumes, alongside improved operating margins compared to the previous year. The company's strategic focus on specialty service growth, physician networks, outpatient expansion, and AI adoption contributed to its positive financial trajectory.
Tenet Healthcare (NYSE: THC) doubles H1 2026 earnings and steps up buybacks
Tenet Healthcare (NYSE: THC) reported a significant increase in profitability for the first half of 2026, with net income available to common shareholders more than doubling to $1,528 million. This surge was primarily driven by higher patient volumes and $826 million in revenue from the Omnibus Agreement related to the wind-down of its contract with CHI. The company also substantially increased its share buybacks, repurchasing $1,360 million worth of shares, and maintained strong liquidity with $2.170 billion in cash and full revolver availability.
Tenet Healthcare director James Bierman sells $1.22m in stock
James L. Bierman, a director at Tenet Healthcare Corp. (NYSE:THC), sold 5,000 shares of the company’s common stock for a total of $1,224,800. The sale occurred on July 27, 2026, with shares trading near their 52-week high, and follows a period of strong financial performance for Tenet Healthcare. The company recently surpassed Wall Street expectations for Q2 2026 and received updated price targets from several firms.
Form 144 TENET HEALTHCARE CORP For: 29 July By Investing.com
This article announces the filing of Form 144 for TENET HEALTHCARE CORP on July 29. It is a brief, news-style piece from Investing.com that primarily serves as a notification regarding this financial filing.
Paola M Arbour Takes Money Off The Table, Sells $2.65M In Tenet Healthcare Stock
Paola M Arbour, EVP at Tenet Healthcare, recently sold 10,878 shares of company stock for a total of $2,653,144. This insider transaction comes as Tenet Healthcare's shares were down by 1.43% on Wednesday. The article also provides a financial overview of Tenet Healthcare, highlighting its revenue growth, debt management, and valuation metrics.
THC5187521 Bond Profile — Key Metrics
This article provides key metrics for the THC5187521 bond, issued by Tenet Healthcare Corp. The bond has a 4.25% coupon rate and matures on June 1, 2029, with an outstanding amount of $1.40 billion USD. Tenet Healthcare Corp. is detailed as a healthcare services provider operating through Hospital Operations and Ambulatory Care segments, founded in 1969 and headquartered in Dallas, TX.
